A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

By Rader J.S.   Clarke-Pearson D.   Moore M.   Carson L.   Holloway R.   Kao M.-S.   Wiznitzer I.   Douglass E.C.  

Gynecologic Oncology, Vol. 91, Iss. 2, 2003-11 ,pp. : 318-325

Elsevier

Access to resources Recommend Favorite

Phase II Study of Gemcitabine, UFT and Leucovorin in Patients with Advanced Pancreatic Cancer

By Kim Tae Won   Kang Hae Jin   Ahn Jin Hee   Lee Keehyun   Chang Heung Moon   Kang Yoon Koo   Lee Jung Shin  

Acta Oncologica, Vol. 41, Iss. 7-8, 2002-11 ,pp. : 689-694

Informa Healthcare

Access to resources Recommend Favorite

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

By Ko Andrew   Dito Elizabeth   Schillinger Brian   Venook Alan   Bergsland Emily   Tempero Margaret  

Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

By Song Hong   Do Young   Chang Heung   Ryu Min   Lee Kyung   Kim Yeul   Hong Dae   Cho Jae   Lee Kyoung   Kim Si  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. : 763-768

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

By Bao Philip   Ramanathan Ramesh   Krasinkas Alyssa   Bahary Nathan   Lembersky Barry   Bartlett David   Hughes Steven   Lee Kenneth   Moser A.   Zeh Herbert  

Annals of Surgical Oncology, Vol. 18, Iss. 4, 2011-04 ,pp. : 1122-1129

Springer Publishing Company

Access to resources Recommend Favorite